Research News

OCRF Research Finds Combination Immunotherapy Promising

(August 19, 2015) Whereas chemotherapy kills cancer cells only while it is being administered, immunotherapy can lead to an adaptive immune response that persists long after treatment is ceased…

Read on

Ovarian Cancer Survival Rates Higher Than Thought

(August 17, 2015) A study from the University of California, Davis found that one-third of women with ovarian cancer survive at least 10 years after diagnosis…

Read on

Study Finds Intraperitoneal Chemotherapy Underutilized

(August 4, 2015) A study published online in the Journal of Clinical Oncology reports that although the use of intraperitoneal chemotherapy (IP)/IV chemotherapy increased significantly at major cancer centers between 2003 and 2012, fewer than 50% of…

Read on

OCRF Research Finds Gene Therapy May Help Patients with Recurrent Ovarian Cancer

(July 30, 2015) Recurrent ovarian cancer patients have more hope today, thanks to OCRF-funded research by David Pepin, PhD at Massachusetts General Hospital. Dr…

Read on

Younger Women with Low Grade Ovarian Cancer Face Worse Outcomes

(July 29, 2015) Research published online in the Journal of Clinical Oncology shows that upon completion of primary therapy, women with low-grade serous carcinoma of the ovary (LGSOC) or peritoneum (LGSPC) who are under the age of 35 and have…

Read on

OCRF Research Shows PARP/Immune Therapy Combo Shows Promise

(July 23, 2015) New OCRF-funded research demonstrates that combining a PARP-inhibitor with immune therapy results in tumor rejection and long-term survival in a mouse model of BRCA1-deficient ovarian cancer…

Read on

Comparison of Clear Cell and Serous Ovarian Cancer- Characteristics and Prognosis

(July 21, 2015) A group of Chinese researchers compared clinical characteristics and prognosis between ovarian clear cell carcinoma (CCC) and serous carcinoma (SC), and found that women with ovarian CCC presented at a younger age and early stage…

Read on

Body Mass Index Impacts Ovarian Cancer Chemotherapy Dosages

(July 19, 2015) Ovarian cancer patients who are overweight or obese are often given less chemotherapy per pound of body weight in order to reduce the toxic side effects associated with higher doses, and this in turn may lower their chances of…

Read on

Bevacizumab with Chemo Improves Survival in Ovarian Cancer with Poor Prognosis

(July 1, 2015) When bevacizumab was added to standard chemotherapy, ovarian cancer patients with a poor prognosis had an overall survival benefit, according to the ICON7 study published online this week in journal The Lancet Oncology…

Read on

ASCO 2015 Update

Several promising advances in the treatment of ovarian cancer were presented at this year’s annual meeting of the American Society of Clinical Oncologists (ASCO). Below is a report from one of our Research Advocates, Katie Hoody…

Read on

OCRF Researchers Find Clues on Mucinous Ovarian Cancer Origins

(June 19, 2015) In a recent study, funded in part by OCRF grants to Dr. Simon Gayther and Dr…

Read on

Investigators Discover How Ovarian Cancer Halts Body’s Natural Defense Against Tumor

(June 18, 2015) A team of researchers, including OCRF grantees Juan Cubillos-Ruiz, PhD, and Alfredo Perales-Puchalt, MD, have discovered how ovarian cancer shuts down immune system cells that would otherwise act as a first line of defense against…

Read on
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]